Vice President and Interim Chief Financial Officer · ImmunoGen, Inc. (IMGN)

Renee Lentini

FY2022 is the first fiscal year CompBrief holds for Renee Lentini as a named executive officer of ImmunoGen; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$965,989

Salary $321,335Stock awards $175,500

6th of 6 named executive officers at ImmunoGen by FY2022 total.

6 named officers on file for ImmunoGen, FY2022

Renee Lentini’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • IMGN’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ImmunoGen’s whole pay program stands against its peers

  • ImmunoGen’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMGN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-20.

Free

Get Renee Lentini’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Renee Lentini compensation by year

ImmunoGen Summary Compensation Table · the one fiscal year held
In US dollars, as ImmunoGen reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$321,335
Stock awards$175,500
Option awards$359,971
Non-equity incentive$102,060
All other$7,123
Total$965,989

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ImmunoGen, Inc. DEF 14A filed April 26, 2023, accession 0001558370-23-006874, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ImmunoGen, Inc. filed document, accession 0001558370-23-006874. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU37,500$186,000—
Option95,700—$5.32
Option45,450—$7.69
Option12,937—$2.31
Option16,387—$4.55
Option22,725—$6.98

Per the Outstanding Equity Awards at Fiscal Year-End table in ImmunoGen, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

56 Form 4 lines since the FY2022 proxy (filed April 26, 2023)
current to 2026-11-20 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-02-12Disposition to the issuer derivative—6,555—0
2024-02-12Disposition to the issuer derivative—12,625—0
2024-02-12Disposition to the issuer derivative—39,370—0
2024-02-12Disposition to the issuer derivative—50,610—0
2024-02-12Disposition to the issuer derivative—10,139—0
2024-02-12Disposition to the issuer derivative—8,250—0
2024-02-12Disposition to the issuer derivative—25,250—0
2024-02-12Disposition to the issuer derivative—53,831—0

The 8 most recent of 56 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments ImmunoGen discloses, by trigger · FY2022
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$360,000—$39,399$507,399
Change in control and involuntary termination$468,000$227,002$39,399$774,401

Per the Potential Payments Upon Termination or Change in Control table in ImmunoGen, Inc.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.

ImmunoGen’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Mark EnyedyPresident and Chief Executive Officer$5,422,421
Michael VasconcellesExecutive Vice President Research, Development and Medical Affairs$3,814,652
Anna BerkenblitSenior Vice President and Chief Medical Officer$1,889,484
Stacy CoenSenior Vice President and Chief Business Officer$1,838,354
Susan AltschullerFormer Senior Vice President and Chief Financial Officer$1,791,733
Renee Lentini · this pageVice President and Interim Chief Financial Officer$965,989

The full ImmunoGen compensation record

free company brief

This page is one person within ImmunoGen's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ImmunoGen proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ImmunoGen's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Renee Lentini's compensation dossier · One-time report. No refunds.